Formycon AG (XTER:FYB) Days Sales Outstanding : 73.05 (As of Dec. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Formycon AG Days Sales Outstanding?

Formycon AG's average Accounts Receivable for the six months ended in Dec. 2024 was €17.12 Mil. Formycon AG's Revenue for the six months ended in Dec. 2024 was €42.78 Mil. Hence, Formycon AG's Days Sales Outstanding for the six months ended in Dec. 2024 was 73.05.

The historical rank and industry rank for Formycon AG's Days Sales Outstanding or its related term are showing as below:

XTER:FYB' s Days Sales Outstanding Range Over the Past 10 Years
Min: 55.53 Med: 70.51 Max: 108.34
Current: 80.08

During the past 13 years, Formycon AG's highest Days Sales Outstanding was 108.34. The lowest was 55.53. And the median was 70.51.

XTER:FYB's Days Sales Outstanding is ranked worse than
57.65% of 843 companies
in the Biotechnology industry
Industry Median: 69.63 vs XTER:FYB: 80.08

Formycon AG's Days Sales Outstanding declined from Dec. 2023 (114.60) to Dec. 2024 (73.05).

Formycon AG Days Sales Outstanding Historical Data

The historical data trend for Formycon AG's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Formycon AG Days Sales Outstanding Chart

Formycon AG Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Days Sales Outstanding

Get a 7-Day Free Trial

62.87

88.77

108.34

60.90

92.48

Formycon AG Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Days Sales Outstanding	Get a 7-Day Free Trial															131.31	94.37	114.60	75.21	73.05

Competitive Comparison of Formycon AG's Days Sales Outstanding

For the Biotechnology subindustry, Formycon AG's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Formycon AG's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Formycon AG's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Formycon AG's Days Sales Outstanding falls into.

Save Embed

;

Save Embed

;

Formycon AG Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Formycon AG's Days Sales Outstanding for the fiscal year that ended in Dec. 2024 is calculated as

	Days Sales Outstanding (A: Dec. 2024 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2023 )	+	Accounts Receivable (A: Dec. 2024 ))	/	count )	/	Revenue (A: Dec. 2024 )	*	Days in Period
=	( (11.612	+	23.693)	/	2 )	/	69.674	*	365
=	17.6525					/	69.674	*	365
=	92.48

Formycon AG's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding (Q: Dec. 2024 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Jun. 2024 )	+	Accounts Receivable (A: Dec. 2024 ))	/	count )	/	Revenue (A: Dec. 2024 )	*	Days in Period
=	( (10.554	+	23.693)	/	2 )	/	42.781	*	365 / 2
=	17.1235					/	42.781	*	365 / 2
=	73.05

Formycon AG (XTER:FYB) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Formycon AG Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Formycon AG's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Formycon AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Formycon AG (XTER:FYB) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

0W4N:UK

Address

Fraunhoferstrasse 15, Martinsried, Planegg, BY, DEU, 82152

Website

https://www.formycon.com

Formycon AG is a globally operating, independent biosimilars specialist with a comprehensive product pipeline and a scalable platform for developing biosimilar drugs for various indications, including ophthalmology, immunology, and immunobiology. Its product, FYB201 (ranibizumab), is an approved biosimilar product for Lucentis, is on the market in the United States and Canada, Europe, the Middle East and North Africa (MENA), and other geographical regions. The other product candidates in its pipeline include FYB202, FYB203, FYB206, FYB207, FYB208, FYB209, and FYB210, which are biosimilar projects being developed for the treatment of various indications. Geographically, the company generates maximum revenue from Switzerland, followed by Germany.

Executives

Dr. Nicola Mikulcik	Board of Directors
Dr. Stefan Glombitza	Board of Directors
Dr. Carsten Brockmeyer	Board of Directors
Dr. Nicolas Combé	Board of Directors

Formycon AG Headlines

No Headlines